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VIAGRA: making you a more potent reviewer
Validity e Were the methods valid? Follow an ABCDE approach
Assignment and accounting
Blindness
Controls
Demographics
SYMPOSIUM: RESEARCHHow to quickly critically
appraise a randomized
control trial
Will CarrollEquality of treatment
Importance e Was the study important? How common is it? Are theeffects clinically meaningful?
Applicability e Can this research be applied to your patients or a
wider group?
GReatness (of benefit) e What is the number needed to treat (or
harm)?
Acceptability e Is it ethical? Would it be acceptable in other health-
care settings? Who funded it?
Box 1Abstract
Being able to critically appraise scientific papers is an important skill. A
thorough and methodical approach is necessary, particularly for peer-
review purposes. However, it is also important to be able to do this
quickly and efficiently. In some circumstances, students and trainees
may be asked to perform a review on an unseen paper as part of an
assessment. With apologies to my erstwhile teacher, David Sackett,
this brief article offers a framework which will allow a fairly complete
review of a randomized controlled trial in 15e20 min. This framework
requires a reviewer to assess the Validity, Importance, Applicability,
GReatness of benefit and Acceptability of any study and is encom-
passed by the acronym VIAGRA.
Keywords assessment tools; evidence-based medicine; randomized
controlled trial; RCT
Introduction: ignore the introduction (and discussion)
<epigraph>The great tragedy of science - the slaying of a
beautiful hypothesis by an ugly fact.
<epigraph source>Thomas Huxley
Reviewing scientific papers is surprisingly difficult. There are
many possible reasons for this, but I believe that there are three
main barriers to reviewing well.
The first is that even with the best of intentions most clinicians
simply do not have the time. As a journal editor with a passion for
research, I perhaps should be setting a good example. However, I
readily admit that my office is littered with journals (and some
books) still in their original wrappings. The second is thatwe are all
approach any topic or studywith a degree of bias. This is difficult to
avoid. I know that I am more likely to be less critical about a paper
that confirms my view of the world and I am sure this tendency
affects other reviewers too. Thirdly, we are swayed by good narra-
tives. As Huxley noted in the 19th century, good science often kills
beautiful hypotheses. Therefore beware the narratives that exist in
your own experience and that of the authors. Whilst placing
research into context is helpful once the study has been completely
assessed, the introduction and discussion sections of any paper
which draw out the authors (and reviewers) narratives on the topic
these should be disregarded completely in the first instance.
Having limited your initial decision about a paper to the
methods and results section it then helps to have a structuredWill Carroll MD FRCPCH, Consultant Paediatrician, University
Hospitals of the North Midlands and Keele University, UK. Conflict of
interest: none declared.
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(see Box 1).Assessing validity: an ABCDE approach
Being able to adequately (rather than completely) review a paper
quickly requires a memorable approach. In determining whether
a study is valid it is useful to first of all determine whether the
research question was adequately defined. On first reading
therefore I try to re-frame any study using a PICO format.
Who were the patients, what was the intervention, what was
the comparison and what was the primary outcome? If I cannot
do this, then the question being addressed is not adequately
focussed (or I am in need of more coffee). To then critically
appraise it I then run through five key questions, as follows.Assignment and accounting
How were participants assigned to their groups and were they all
accounted for at the end of the study?
If this is a randomized controlled trial then the assignment
should be random and this should be clearly described. Histori-
cally, reviewers and researchers have worried a lot about the
randomization process as this can lead to bias being introduced.
There is probably not a ‘perfect’ solution to randomization.
However, clinicians should be at least one step removed from
randomization wherever possible. Otherwise we know that there
is a temptation to enter participants into active treatment groups.
Clinicians and participants should have the allocation sequence
concealed from them.
Once individuals are assigned to a group it is crucial to track
their progress through the study and carefully check to see
whether everyone entered into the study is accounted for. In
many better studies there is a flow diagram explaining this
(Figure 1).Blinding
Blinding is an importantpart of any trial. It is not alwayspossiblebut
if it is not done, or done poorly then it can lead to bias as researchers
or participants will know which treatment arm they are in. 2019 Elsevier Ltd. All rights reserved.
andomized control trial, Paediatrics and Child Health, https://doi.org/
Children identified for 
study (n=50)
Informed consent 
(n=42)
Declined participation 
(n=8)
Randomised to FP 
(n=18)
Randomised to SAL/FP 
(n=21)
Week 0
Week -4
Week 4
Randomised to SAL/FP 
(n=21)
Randomised to FP 
(n=16)
Week 8
Randomised to SAL/FP 
(n=21)
Randomised to FP 
(n=16)
Withdrawn prior to 
randomisation (n=3)
1 exacerbation, 2 DNA
Withdrawn post 
randomisation (n=2)
1 exacerbation, 2 DNA
Figure 1 Example of a flow diagram. *Data taken from Carroll et al. 2010. See references and further reading. FP ¼ fluticasone propionate, SAL ¼
salmeterol.
SYMPOSIUM: RESEARCHSometimes a common sense approach is required in
assessing this and some knowledge of the treatments being
offered is helpful. If a treatment is known to have very
predictable effects or side effects then blinding might be
more difficult. For instance, a medication with a very
particular taste, appearance or smell can be difficult to
blind, particularly if individuals in the study have taken it
before.
An example of a treatment that is difficult to blind for is
nebulized adrenaline (see references and further reading).
When this was compared against nebulized 0.9% saline in a
research study that I helped to conduct, the researchers became
aware quite quickly that babies receiving adrenaline would
often look pale and become tachycardic. It was fairly easy for
parents and clinicians to guess which group a child had been
randomized to.Controls
Where were controls recruited from? Was this the same source as
participants or were they recruited from elsewhere. This may
well affect the validity of a study.Demographics
One way to check quickly to see if controls are from a different
source or likely to behave differently from the intervention group
is to check through the demographics for intervention and con-
trol groups. These should be reported and all the characteristics
that might influence outcome should be listed e.g. age and sex.
Be careful with small studies which assume that because there is
not a statistically significant difference between measured de-
mographics that these are not important. If there is a difference
then ask yourself, ‘could this account for part or all of the re-
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It is important to check the protocol description and ensure that
the control groups is treated equally to the intervention group in
all aspects aside from the experimental intervention. Many
studies purport to study a single treatment but in reality are
studying a multitude of effects.
If treatment groups spend longer with healthcare pro-
fessionals then outcomes might be influenced by this extra con-
tact time. Therefore, to be valid then this must be accounted for
in experimental design. If it seems likely to have occurred due to
extra visits or interventions in the intervention group then this is
an important limitation.
Is the study important?
Deciding whether a study addresses an important topic is
somewhat subjective. Small improvements in outcomes for
important or common diseases can be very important. All im-
provements in care and outcome are of course very important to
families and clinicians. However, it is helpful to ask some
questions of any study at the outset.
It is useful to see if the researchers have undertaken a power
calculation. This gives an indication of whether the study was
adequately powered to look for any observed effect. I then
perform a ‘sense check’ on whether this effect is clinically
important. For instance, if the effect is on a clinical score, has this
been validated and do the individual components of the score all
have clinical importance.
Some studies measure outcomes that are removed from clin-
ical outcomes that matter. A reduction in C-reactive protein
levels without reduction in hospital stays or mortality is probably
unimportant. A reduction in wheeze (audibility) is often reported
as part of a composite measure of respiratory distress, but this 2019 Elsevier Ltd. All rights reserved.
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SYMPOSIUM: RESEARCHmay not equate to reduced requirement for oxygen or hospitali-
zation. Even these may be dependent upon the doctors and
nurses judgement and are less helpful than ‘hard’ end points
such as death and/or disability.
Is the study applicable (to my patients)?Who, where and when?
This is not always easy to answer. However, it is helpful to
consider the Who, where and how of any study.
Who is particularly important. Studies in very different pop-
ulation groups to your own may significantly limit the applica-
bility of a study to your own practice. Paediatricians are very
aware that many adult studies are erroneously applied to pae-
diatric populations so age is a particularly important consider-
ation. However, there are other important considerations. For
instance, some conditions have different responses to treatment
that are dependent upon ethnicity.
Where is also important. Some of the settings for reported
studies are so different in context from your own that research
might not be easily transferred. Children in developing countries
are likely to present to hospital (and researchers) much later and
therefore results may be misleading for those working in the
developed world and vice versa.
When is important when considering older studies. In some
fields the clinical treatment has evolved so much that reported
interventions may no longer be applicable. For instance studies
of asthma treatments in the era prior to widespread use of
inhaled corticosteroids.
Assessing the GReatness of benefitBe careful with small or very large studies
Alongside a subjective judgement about the importance of a
particular treatment, it is useful to consider in real terms how
great the observed benefit is. Many recent studies will be powered
to detect a ‘minimally important clinical difference’. It is helpful
to see whether this has been determined by anyone other the
researchers themselves. As patients and families become more
involved with research, it is likely that end-points will begin to
become more relevant.
Small studies which report a very large effects must be viewed
with caution. It helps to look carefully at any reported confidence
intervals. When these are wide and particularly if the p value for
any observed effect is close to 0.05 be very careful. RememberPAEDIATRICS AND CHILD HEALTH xxx:xxx 3
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Some very large studies report a very high level of statistical
significance, but a small clinical difference. A judgement here is
required in the reviewer about whether any such observations
are important. For instance an improvement of 2% in lung
function of a child with asthma is unlikely to be of clinical sig-
nificance to the individual but if a study is large enough it might
be able to detect it.
Two useful quick checks of benefit are to calculate the
Number Needed to Treat (NNT) and the Number Needed to
Harm (NNH) for any proposed intervention.
Acceptability
A final check is to see if the proposed intervention is likely to be
acceptable to your own patients. This may depend upon cultural,
religious and societal expectations. It is useful to see whether
ethical approval has been sought and given e and if so from
where. It is very unlikely that a recent randomized controlled
trial will be published without ethical approval.
As a final check, I routinely check to see who has funded the
research and make a judgement about whether this may have
introduced bias either into the protocol design or the presenta-
tion of the results. Funders, such as drug companies may have a
significant financial interest in some studies being published.
Some sources of funding might not be acceptable or at the very
least questionable e.g. the tobacco industry. A
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